TMFEBCapital

Todd Campbell

TMFEBCapital’s Activity

Yesterday

NL

Article

EBCapitalMarkets published an article 11:19 AM

Earnings Roundup: What You Need to Know About Gilead's Blockbuster Quarter

Gilead (GILD) posted blockbuster sales for Sovaldi, outpacing Johnson & Johnson's (JNJ) Olysio.

Tue Apr 22

NL

Article

EBCapitalMarkets published an article 2:26 PM

Earnings Roundup: Centene's Medicaid Miracle

Centene (CNC) joined United Healthcare (UNH) in reporting impressive Medicaid revenue, setting the stage for Molina (MOH) to beat when it reports on May 1st.

NL

Article

EBCapitalMarkets published an article 11:45 AM

Earnings Roundup: athenahealth's Disappointing Quarter

The market for healthcare IT has never been stronger, but that did little to calm athenahealth's (ATHN) investors' worry over uninspiring earnings.

NL

Article

EBCapitalMarkets published an article 10:08 AM

Allergan: Here's Why Ackman and Valeant Want the Botox Maker

Here's what you need to know about Valeant's (VRX) planned $45 billion acquisition of Allergan (AGN),

Mon Apr 21

NL

Article

EBCapitalMarkets published an article 4:45 PM

Earnings Roundup: Baxter International Grows Ahead of Its Spin-Off

Sales at Baxter (BAX) biopharma and medical device businesses headed higher in the first quarter, suggesting a bright future for Baxter's planned separation of its biopharma and medical device business next year.

Thu Apr 17

NL

Article

EBCapitalMarkets published an article 3:59 PM

Earnings Roundup: Did Obamacare Swamp United Healthcare's Quarter?

Medicaid membership surged at United Healthcare (UNH) in Q1, offsetting headwinds tied to Obamacare fees and higher taxes, and suggesting strong results for Medicaid insurers Molina (MOH) and Centene (CNC).

NL

Article

EBCapitalMarkets published an article 12:57 PM

Earnings Roundup: Look Beyond Abbott Labs' Short-term Bumps

A recall in Abbott Labs (ABT) nutrition segment gave Mead Johnson (MJN) an edge, but that and other short-term hurdles shouldn't distract investors from the company's long-term opportunity.

NL

Article

EBCapitalMarkets published an article 11:43 AM

Earnings Roundup: St. Jude's 1 Bright Spot

St Jude's (STJ) electrophysiology business is the one bright spot in an otherwise dim earnings report.

Wed Apr 16

NL

Article

EBCapitalMarkets published an article 2:18 PM

Warfarin's Loss is Johnson & Johnson's Gain

Factor Xa-inhibiting anticoagulants like Johnson & Johnson's Xarelto are rapidly winning prescriptions away from warfarin and Boehringer's Pradaxa.

NL

Article

EBCapitalMarkets published an article 12:21 PM

Johnson & Johnson's New Diabetes Drug: A Blockbuster in the Making?

Johnson's Invokana is about to face a host of new SGLT2 competitors from AstraZeneca, Merck, and Eli Lilly.

NL

Article

EBCapitalMarkets published an article 11:02 AM

3 Reasons Rite Aid Continues to Crush the Market

Shares in Rite Aid (RAD) may keep heading higher thanks to these three reasons.

NL

Article

EBCapitalMarkets published an article 10:53 AM

How Big Is the Threat to This Johnson & Johnson Blockbuster?

Growth for Johnson & Johnson's (JNJ) blockbuster Zytiga is being weighed down by Medivation (MDVN) and Astellas (ALPMY) Xtandi.

NL

Article

EBCapitalMarkets published an article 10:28 AM

Earnings Roundup: Johnson & Johnson Results Are Better Than They Appear

Slow growth from medical device and consumer goods masked robust sales in Johnson & Johnson's drug business.

Tue Apr 15

NL

Article

EBCapitalMarkets published an article 5:29 PM

Down 17%: Is Isis Pharmaceuticals Worth Buying Now?

Despite a deep product pipeline of intriguing RNAi drugs, shares in Isis (ISIS) have toppled this year. Here's what you need to know about Isis and the catalysts likely to move its shares in the coming year.

NL

Article

EBCapitalMarkets published an article 4:55 PM

Earnings Primer: What's on Deck for Amgen Inc. and Biogen Idec Inc.

Here's what you need to know about Amgen (AMGN) and Biogen's (BIIB) upcoming first quarter earnings report.

NL

Article

EBCapitalMarkets published an article 1:58 PM

Earnings Primer: What's on Deck for Celgene, AbbVie, and Gilead

Here's what you need to know about Celgene (CELG), AbbVie (ABBV), and Gilead (GILD) before they report their first quarter earnings later this month.

NL

Article

EBCapitalMarkets published an article 1:02 PM

Earnings Roundup: Rite Aid Impresses

Here's what you need to know about Rite Aid's recent earnings and its plans to challenge market share leaders CVS and Walgreen.

Mon Apr 14

NL

Article

EBCapitalMarkets published an article 1:06 PM

1 Stock Helping Revolutionize Diabetes Monitoring

New products in development with partners Johnson & Johnson and Tandem could help Dexcom outmaneuver its chief competitor, Medtronic.

Sun Apr 13

NL

Article

EBCapitalMarkets published an article 8:17 PM

Better Buy: Illumina, Inc. Vs. Intuitive Surgical, Inc.

Investors have bid up shares in Illumina (ILMN) and Intuitive Surgical (ISRG) to frothy levels in the past. With markets off their highs, is one a better buy than the other?

Fri Apr 11

NL

Article

EBCapitalMarkets published an article 3:20 PM

Impax Breathes New Life Into Stalled Parkinson's Drug

Impax's (IPXL) stumbles in bringing Rytary, it's long lasting Parkinson's drug, to market may finally be over given its re-filed with the FDA for approval.

Show More Activity ...

CAPS Stats & Trivia

CAPS Player Rating < 20
Player Rank 62457 out of 74856
Score -212.60
Score Change Today -10.93
Accuracy 29.41%
Active Picks 34
Total Picks 34
Best Pick SAM (+21.63)
Worst Pick BJRI (-37.00)
Average Score per Pick -6.25
Charms Earned 6
Highest Rated Favorite No Favorites Selected
Go to TMFEBCapital’s CAPS page

Boards Stats & Trivia

Board Posts 0
Recs Received 0
People who have rec'd these posts 0
Recs to Posts Ratio (last 30 days) N/A
Threads Started 0
Threads Started Percentage 0.00 %
Most Frequent Board N/A
Very First Post N/A
Percentage of Posts Rec'd 100.00 %
Show TMFEBCapital’s 10 Latest Posts